CoChat
Sign Up
Cited by 76Angiogenesis and VEGF in CancerMesenchymal stem cell researchExtracellular vesicles in disease

Are Endothelial Progenitor Cells the Real Solution for Cardiovascular Diseases? Focus on Controversies and Perspectives

Open access
Balistreri, Carmela R., Buffa, Silvio, Pisano, Calogera, Lio, Domenico, Ruvolo, Giovanni, Mazzesi, Giuseppe·2015·BioMed Research International
DOI 10.1155/2015/835934PMC PMC4609774
Open this paper in CoChat — free accountOpen PDF

Abstract

Advanced knowledge in the field of stem cell biology and their ability to provide a cue for counteracting several diseases are leading numerous researchers to focus their attention on “regenerative medicine” as possible solutions for cardiovascular diseases (CVDs). However, the lack of consistent evidence in this arena has hampered the clinical application. The same condition affects the research on endothelial progenitor cells (EPCs), creating more confusion than comprehension. In this review, this aspect is discussed with particular emphasis. In particular, we describe biology and physiology of EPCs, outline their clinical relevance as both new predictive, diagnostic, and prognostic CVD biomarkers and therapeutic agents, discuss advantages, disadvantages, and conflicting data about their use as possible solutions for vascular impairment and clinical applications, and finally underline a very crucial aspect of EPCs “characterization and definition,” which seems to be the real cause of large heterogeneity existing in literature data on this topic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2015/835934

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lack of standardized criteria for characterizing and identifying EPCs, age of donors and their clinical conditions, and ethnicity of populations may negatively affect the viability and function of EPCs.

    “Lack of standardized criteria for characterizing and identifying EPCs, age of donors and their clinical conditions, and ethnicity of populations may negatively affect the viability and function of EPCs [241].”

    From Liver tissue engineering using decellularized scaffolds: Current progress, challenges, and opportunities (2024) · cites this paper as [241]

    Section 5.1 says that detection methods, patients’ age and clinical conditions, and population ethnicity may influence EPC levels and viability. Section 3.3.1 links ageing to altered EPC function and viability, while Sections 5.4 and 6 call for standardized identification criteria. The paper does not say that every listed factor negatively affects EPC viability and function; methodological differences are discussed chiefly as affecting EPC evaluation. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 76

  1. [2]Edwards R. D. Population aging, the dependency burden, and challenges facing preventive medicine Preventive Medicine 2012 55 6 533 534 10.1016/j.ypmed.2012.07.025 2-s2.0-84872380883 22890023 · DOI
  2. [4]Opie L. H. Dalby A. J. Cardiovascular prevention: lifestyle and statins—competitors or companions? South African Medical Journal 2014 104 3 168 173 10.7196/samj.7942 2-s2.0-84894813042 24897816 · DOI
  3. [5]Mozaffarian D. Benjamin E. J. Go A. S. Heart disease and stroke statistics—2015 update: a report from the American Heart Association Circulation 2015 131 4 e29 e322 10.1161/cir.0000000000000152 2-s2.0-84922381210 25520374 · DOI · Paper page
  4. [6]Institute of Medicine Fuster V. Kelly B. B. Committee on preventing the global epidemic of cardiovascular disease: meeting the challenges in developing countries Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health 2010 Washington, DC, USA National Academies Press 20945571
  5. [7]Gersh B. J. Simari R. D. Behfar A. Terzic C. M. Terzic A. Cardiac cell repair therapy: a clinical perspective Mayo Clinic Proceedings 2009 84 10 876 892 10.4065/84.10.876 2-s2.0-70350484991 19797777 PMC2755807 · DOI
  6. [8]Sadahiro T. Yamanaka S. Ieda M. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications Circulation Research 2015 116 8 1378 1391 10.1161/circresaha.116.305374 25858064 · DOI
  7. [9]Goldschmidt-Clermont P. J. Dong C. Seo D. M. Velazquez O. C. Atherosclerosis, inflammation, genetics, and stem cells: 2012 update Current Atherosclerosis Reports 2012 14 3 201 210 10.1007/s11883-012-0244-1 2-s2.0-84861235459 22476914 PMC3537163 · DOI
  8. [10]Cheema F. H. Polvani G. Argenziano M. Pesce M. Combining stem cells and tissue engineering in cardiovascular repair—a step forward to derivation of novel implants with enhanced function and self-renewal characteristics Recent Patents on Cardiovascular Drug Discovery 2012 7 1 10 20 10.2174/157489012799362403 2-s2.0-84857756792 22280334 · DOI
  9. [11]Goichberg P. Chang J. Liao R. Leri A. Cardiac stem cells: biology and clinical applications Antioxidants & Redox Signaling 2014 21 14 2002 2017 10.1089/ars.2014.5875 2-s2.0-84913588453 24597850 PMC4208604 · DOI
  10. [12]Asahara T. Murohara T. Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis Science 1997 275 5302 964 967 10.1126/science.275.5302.964 2-s2.0-0031019745 9020076 · DOI · Paper page
  11. [13]Resch T. Pircher A. Kähler C. M. Pratschke J. Hilbe W. Endothelial progenitor cells: current issues on characterization and challenging clinical applications Stem Cell Reviews 2012 8 3 926 939 10.1007/s12015-011-9332-9 2-s2.0-84865564286 22095429 · DOI
  12. [14]Urbich C. Dimmeler S. Endothelial progenitor cells: functional characterization Trends in Cardiovascular Medicine 2004 14 8 318 322 10.1016/j.tcm.2004.10.001 2-s2.0-18744362545 15596109 · DOI
  13. [15]Pelosi E. Castelli G. Testa U. Endothelial progenitors Blood Cells, Molecules, & Diseases 2014 52 4 186 194 10.1016/j.bcmd.2013.11.004 2-s2.0-84895548526 24332583 · DOI
  14. [16]Wojakowski W. Landmesser U. Bachowski R. Jadczyk T. Tendera M. Mobilization of stem and progenitor cells in cardiovascular diseases Leukemia 2012 26 1 23 33 10.1038/leu.2011.184 2-s2.0-84856708388 21788948 · DOI
  15. [17]Schmeisser A. Garlichs C. D. Zhang H. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions Cardiovascular Research 2001 49 3 671 680 10.1016/s0008-6363(00)00270-4 2-s2.0-0035895774 11166280 · DOI
  16. [18]Watt S. M. Gullo F. van der Garde M. The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential British Medical Bulletin 2013 108 1 25 53 10.1093/bmb/ldt031 2-s2.0-84890034484 24152971 PMC3842875 · DOI
  17. [19]Lv F.-J. Tuan R. S. Cheung K. M. C. Leung V. Y. L. Concise review: the surface markers and identity of human mesenchymal stem cells Stem Cells 2014 32 6 1408 1419 10.1002/stem.1681 2-s2.0-84901477349 24578244 · DOI
  18. [20]Murray I. R. West C. C. Hardy W. R. Natural history of mesenchymal stem cells, from vessel walls to culture vessels Cellular and Molecular Life Sciences 2014 71 8 1353 1374 10.1007/s00018-013-1462-6 2-s2.0-84897114196 24158496 PMC11113613 · DOI
  19. [21]Li D.-W. Liu Z.-Q. Wei J. Liu Y. Hu L.-S. Contribution of endothelial progenitor cells to neovascularization (review) International Journal of Molecular Medicine 2012 30 5 1000 1006 10.3892/ijmm.2012.1108 2-s2.0-84866628466 22922670 · DOI
  20. [22]Hoenig M. R. Bianchi C. Sellke F. W. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis Current Drug Targets 2008 9 5 422 435 10.2174/138945008784221215 2-s2.0-44949206575 18473772 · DOI
  21. [23]Gallagher K. A. Liu Z.-J. Xiao M. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α The Journal of Clinical Investigation 2007 117 5 1249 1259 10.1172/jci29710 2-s2.0-34248213008 17476357 PMC1857264 · DOI
  22. [24]Povsic T. J. Najjar S. S. Prather K. EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy Journal of Thrombosis and Thrombolysis 2013 36 4 375 383 10.1007/s11239-013-0944-6 2-s2.0-84889093566 23700090 PMC4008147 · DOI
  23. [25]Ito H. Rovira I. I. Bloom M. L. Endothelial progenitor cells as putative targets for angiostatin Cancer Research 1999 59 23 5875 5877 2-s2.0-0033406794 10606226
  24. [26]Williamson K. Stringer S. E. Alexander M. Y. Endothelial progenitor cells enter the aging arena Frontiers in Physiology 2012 3, article 30 10.3389/fphys.2012.00030 2-s2.0-84866282015 PMC3282536 22363299 · DOI
  25. [27]Felice F. Barsotti M. C. Poredos P. Balbarini A. Di Stefano R. Effect of aging on metabolic pathways in endothelial progenitor cells Current Pharmaceutical Design 2013 19 13 2351 2365 10.2174/1381612811319130003 2-s2.0-84877795568 23173584 · DOI
  26. [28]Lin C.-P. Lin F.-Y. Huang P.-H. Endothelial progenitor cell dysfunction in cardiovascular diseases: role of reactive oxygen species and inflammation BioMed Research International 2013 2013 10 845037 10.1155/2013/845037 2-s2.0-84874602308 PMC3591199 23484163 · DOI
  27. [29]Rodiño-Janeiro B. K. Paradela-Dobarro B. Castiñeiras-Landeira M. I. Raposeiras-Roubín S. González-Juanatey J. R. Álvarez E. Current status of NADPH oxidase research in cardiovascular pharmacology Vascular Health and Risk Management 2013 9 1 401 428 10.2147/vhrm.s33053 2-s2.0-84889847835 23983473 PMC3750863 · DOI
  28. [30]Werner N. Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 2 257 266 10.1161/01.atv.0000198239.41189.5d 2-s2.0-33644871364 16322535 · DOI
  29. [31]de Ciuceis C. Pilu A. Cappelli C. Decreased number of circulating endothelial progenitor cells in patients with Graves' hyperthyroidism Journal of Endocrinological Investigation 2011 34 5 335 339 10.3275/7136 2-s2.0-79960233842 20585201 · DOI
  30. [32]Shakoor S. K. A. Aldibbiat A. Ingoe L. E. Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy The Journal of Clinical Endocrinology & Metabolism 2010 95 1 319 322 10.1210/jc.2009-1421 2-s2.0-75149171301 19897678 · DOI
  31. [33]Fadini G. P. de Kreutzenberg S. Albiero M. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 5 997 1004 10.1161/atvbaha.107.159558 2-s2.0-42149094460 18276910 · DOI
  32. [34]Sugawara J. Mitsui-Saito M. Hoshiai T. Hayashi C. Kimura Y. Okamura K. Circulating endothelial progenitor cells during human pregnancy The Journal of Clinical Endocrinology & Metabolism 2005 90 3 1845 1848 10.1210/jc.2004-0541 2-s2.0-15944407669 15585564 · DOI
  33. [35]Lee P. S. Poh K. K. Endothelial progenitor cells in cardiovascular diseases World Journal of Stem Cells 2014 6 3 355 366 10.4252/wjsc.v6.i3.355 25126384 PMC4131276 · DOI
  34. [36]Fernández J. M. Rosado-Álvarez D. da Silva Grigoletto M. E. Moderate-to-high-intensity training and a hypocaloric Mediterranean diet enhance endothelial progenitor cells and fitness in subjects with the metabolic syndrome Clinical Science 2012 123 6 361 373 10.1042/cs20110477 2-s2.0-84862553039 22489903 · DOI
  35. [37]Marin C. Ramirez R. Delgado-Lista J. Mediterranean diet reduces endothelial damage and improves the regenerative capacity of endothelium The American Journal of Clinical Nutrition 2011 93 2 267 274 10.3945/ajcn.110.006866 2-s2.0-79251522858 21123460 · DOI
  36. [38]Aird W. C. Endothelium in health and disease Pharmacological Reports 2008 60 1 139 143 2-s2.0-42549157140 18276995
  37. [39]van Ierssel S. H. Jorens P. G. van Craenenbroeck E. M. Conraads V. M. The endothelium, a protagonist in the pathophysiology of critical illness: focus on cellular markers BioMed Research International 2014 2014 10 985813 10.1155/2014/985813 2-s2.0-84899561074 PMC3988750 24800259 · DOI
  38. [40]Favero G. Paganelli C. Buffoli B. Rodella L. F. Rezzani R. Endothelium and its alterations in cardiovascular diseases: life style intervention BioMed Research International 2014 2014 28 801896 10.1155/2014/801896 2-s2.0-84897850189 PMC3955677 24719887 · DOI
  39. [41]Shantsila E. Watson T. Lip G. Y. H. Endothelial progenitor cells in cardiovascular disorders Journal of the American College of Cardiology 2007 49 7 741 752 10.1016/j.jacc.2006.09.050 2-s2.0-33846969572 17306702 · DOI · Paper page
  40. [42]King T. F. J. McDermott J. H. Endothelial progenitor cells and cardiovascular disease Journal of Stem Cells 2014 9 2 93 106 2-s2.0-84922479809 25158158
  41. [43]Obi S. Yamamoto K. Ando J. Effects of shear stress on endothelial progenitor cells Journal of Biomedical Nanotechnology 2014 10 10 2586 2597 10.1166/jbn.2014.2014 2-s2.0-84905653351 25992410 · DOI
  42. [44]Ma F. Morancho A. Montaner J. Rosell A. Endothelial progenitor cells and revascularization following stroke Brain Research 2015 10.1016/j.brainres.2015.02.010 25725381 · DOI
  43. [46]Kocher A. A. Schuster M. D. Szabolcs M. J. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function Nature Medicine 2001 7 4 430 436 10.1038/86498 2-s2.0-0035044085 11283669 · DOI
  44. [47]Kawamoto A. Asahara T. Losordo D. W. Transplantation of endothelial progenitor cells for therapeutic neovascularization Cardiovascular Radiation Medicine 2002 3 3-4 221 225 10.1016/S1522-1865(03)00082-9 2-s2.0-0142227736 12974378 · DOI
  45. [48]Orlic D. Kajstura J. Chimenti S. Bodine D. M. Leri A. Anversa P. Bone marrow stem cells regenerate infarcted myocardium Pediatric Transplantation 2003 7 3 86 88 2-s2.0-0347926542 12603699
  46. [49]Naruse K. Hamada Y. Nakashima E. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy Diabetes 2005 54 6 1823 1828 10.2337/diabetes.54.6.1823 2-s2.0-20044366933 15919805 · DOI
  47. [50]Shyu W.-C. Lin S.-Z. Chiang M.-F. Su C.-Y. Li H. Intracerebral peripheral blood stem cell (CD34+) implantation induces neuroplasticity by enhancing β1 integrin-mediated angiogenesis in chronic stroke rats The Journal of Neuroscience 2006 26 13 3444 3453 10.1523/jneurosci.5165-05.2006 2-s2.0-33645454580 16571751 PMC6673856 · DOI
  48. [51]Gómez-Navarro J. Contreras J. L. Arafat W. Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model Gene Therapy 2000 7 1 43 52 10.1038/sj.gt.3301054 2-s2.0-0343776138 10680015 · DOI
  49. [52]Ohtsuka M. Takano H. Zou Y. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization The FASEB Journal 2004 18 7 851 853 2-s2.0-4644247808 15001565
  50. [53]Strauer B. E. Brehm M. Zeus T. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans Circulation 2002 106 15 1913 1918 10.1161/01.cir.0000034046.87607.1c 2-s2.0-0037044406 12370212 · DOI
  51. [54]Assmus B. Schächinger V. Teupe C. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI) Circulation 2002 106 24 3009 3017 10.1161/01.cir.0000043246.74879.cd 2-s2.0-0037058848 12473544 · DOI
  52. [55]Fernández-Avilés F. San Román J. A. García-Frade J. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction Circulation Research 2004 95 7 742 748 10.1161/01.res.0000144798.54040.ed 2-s2.0-4944241806 15358665 · DOI
  53. [56]Schächinger V. Assmus B. Britten M. B. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial Journal of the American College of Cardiology 2004 44 8 1690 1699 10.1016/j.jacc.2004.08.014 2-s2.0-5644236574 15489105 · DOI
  54. [57]Leistner D. M. Fischer-Rasokat U. Honold J. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy Clinical Research in Cardiology 2011 100 10 925 934 10.1007/s00392-011-0327-y 2-s2.0-80054721891 21633921 · DOI
  55. [58]Gennari M. Gambini E. Bassetti B. Capogrossi M. Pompilio G. Emerging treatment options for refractory angina pectoris: ranolazine, shock wave treatment, and cell-based therapies Reviews in Cardiovascular Medicine 2014 15 1 31 37 10.3909/ricm0672 2-s2.0-84901921259 24762464 · DOI
  56. [59]Tongers J. Losordo D. W. Frontiers in nephrology: the evolving therapeutic applications of endothelial progenitor cells Journal of the American Society of Nephrology 2007 18 11 2843 2852 10.1681/asn.2007050597 2-s2.0-35848963199 17942950 · DOI
  57. [60]Tse H.-F. Kwong Y.-L. Chan J. K. F. Lo G. Ho C.-L. Lau C.-P. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation The Lancet 2003 361 9351 47 49 10.1016/s0140-6736(03)12111-3 2-s2.0-0037417506 12517468 · DOI
  58. [61]Hamano K. Nishida M. Hirata K. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results Japanese Circulation Journal 2001 65 9 845 847 10.1253/jcj.65.845 2-s2.0-0034841919 11548889 · DOI
  59. [62]Perin E. C. Dohmann H. F. R. Borojevic R. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure Circulation 2003 107 18 2294 2302 10.1161/01.CIR.0000070596.30552.8B 2-s2.0-0038701741 12707230 · DOI
  60. [63]Tateishi-Yuyama E. Matsubara H. Murohara T. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial The Lancet 2002 360 9331 427 435 10.1016/s0140-6736(02)09670-8 2-s2.0-0037055666 12241713 · DOI
  61. [64]Matoba S. Tatsumi T. Murohara T. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia American Heart Journal 2008 156 5 1010 1018 10.1016/j.ahj.2008.06.025 2-s2.0-54349125024 19061721 · DOI
  62. [65]Yamamoto K. Kondo T. Suzuki S. Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 12 e192 e196 10.1161/01.atv.0000147730.78953.60 2-s2.0-21644466806 15486312 · DOI
  63. [66]Lenk K. Adams V. Lurz P. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia European Heart Journal 2005 26 18 1903 1909 10.1093/eurheartj/ehi285 2-s2.0-24344492417 15855189 · DOI
  64. [67]Erbs S. Linke A. Adams V. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study Circulation Research 2005 97 8 756 762 10.1161/01.res.0000185811.71306.8b 2-s2.0-26844545832 16151021 · DOI
  65. [68]Pearson J. D. Endothelial progenitor cells—hype or hope? Journal of Thrombosis and Haemostasis 2009 7 2 255 262 10.1111/j.1538-7836.2008.03214.x 2-s2.0-59049096146 19207362 · DOI
  66. [69]Yamahara K. Itoh H. Potential use of endothelial progenitor cells for regeneration of the vasculature Therapeutic Advances in Cardiovascular Disease 2009 3 1 17 27 10.1177/1753944708097728 2-s2.0-67849087386 19144668 · DOI
  67. [70]Siddique A. Shantsila E. Lip G. Y. Varma C. Endothelial progenitor cells: what use for the cardiologist? Journal of Angiogenesis Research 2010 2, article 6 10.1186/2040-2384-2-6 2-s2.0-77953459359 PMC2834645 20298532 · DOI
  68. [71]Pasquier E. Dias S. Endothelial progenitor cells: hope beyond controversy Current Cancer Drug Targets 2010 10 8 914 921 10.2174/156800910793358041 2-s2.0-79953694441 20718700 · DOI
  69. [72]Madonna R. De Caterina R. Circulating endothelial progenitor cells: do they live up to their name? Vascular Pharmacology 2015 67–69 2 5 10.1016/j.vph.2015.02.018 25869520 · DOI
  70. [73]Van Craenenbroeck E. M. Van Craenenbroeck A. H. Van Ierssel S. Quantification of circulating CD34+/KDR+/CD45dim endothelial progenitor cells: analytical considerations International Journal of Cardiology 2013 167 5 1688 1695 10.1016/j.ijcard.2012.10.047 2-s2.0-84883267464 23171577 · DOI
  71. [74]Lee L. C. Chen C.-S. Choong P.-F. Low A. Tan H. C. Poh K. K. Time-dependent dynamic mobilization of circulating progenitor cells during percutaneous coronary intervention in diabetics International Journal of Cardiology 2010 142 2 199 201 10.1016/j.ijcard.2008.11.198 2-s2.0-77953287081 19157595 · DOI
  72. [75]Hristov M. Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance Journal of Cellular and Molecular Medicine 2004 8 4 498 508 10.1111/j.1582-4934.2004.tb00474.x 2-s2.0-16644369282 15601578 PMC6740289 · DOI
  73. [76]Medina R. J. O'Neill C. L. Sweeney M. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities BMC Medical Genomics 2010 3, article 18 10.1186/1755-8794-3-18 2-s2.0-77952065242 PMC2881111 20465783 · DOI
  74. [77]Sieveking D. P. Buckle A. Celermajer D. S. Ng M. K. C. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay Journal of the American College of Cardiology 2008 51 6 660 668 10.1016/j.jacc.2007.09.059 2-s2.0-38749090588 18261686 · DOI
  75. [79]Kane N. M. Xiao Q. Baker A. H. Luo Z. Xu Q. Emanueli C. Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re(generation) Pharmacology and Therapeutics 2011 129 1 29 49 10.1016/j.pharmthera.2010.10.004 2-s2.0-78650512220 20965210 · DOI
  76. [80]He J. Xiao Z. Chen X. The expression of functional toll-like receptor 4 is associated with proliferation and maintenance of stem cell phenotype in endothelial progenitor cells (EPCs) Journal of Cellular Biochemistry 2010 111 1 179 186 10.1002/jcb.22686 2-s2.0-77957126896 20506307 · DOI

Cited by

Sorted by citations

Authors
Balistreri, C. R., Buffa, S., Pisano, C., Lio, D., Ruvolo, G., & Mazzesi, G.
Affiliations
  • University of Palermo (IT)
  • Sapienza University of Rome (IT)
Corresponding author
Balistreri, Carmela R.
ORCID
Venue
BioMed Research International
Publisher
Hindawi Limited
Published
2015
Volume
2015
Pages
1-17
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
DOI
10.1155/2015/835934
PMC
PMC4609774
OpenAlex
W2145444355
Cited by
76
References
4
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 4 · 2022: 6 · 2021: 12 · 2020: 6 · 2019: 7 · 2018: 11 · 2017: 6 · 2016: 12
FWCI
0.94
Type
journal article
Language
en
Open access
Licence
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
endothelial progenitor cells, cardiovascular disease, regenerative medicine, stem cell therapy, cardiovascular biomarkers, vascular dysfunction, clinical translation
MeSH terms
Bone Marrow Cells, Cardiovascular Diseases, Endothelium, Vascular, Humans, Neovascularization, Physiologic, Stem Cell Transplantation, Regenerative Medicine, Endothelial Progenitor Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review